% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Galldiks:837425,
      author       = {Galldiks, Norbert and Stegmayr, Carina and Willuweit, Antje
                      and Langen, Karl-Josef},
      title        = {{P}ositron emission tomography imaging in diffuse intrinsic
                      pontine glioma{INM}},
      journal      = {Annals of translational medicine},
      volume       = {5},
      number       = {15},
      issn         = {2305-5839},
      address      = {Shatin, NT},
      publisher    = {AME Publishing Company},
      reportid     = {FZJ-2017-06350},
      pages        = {312 - 312},
      year         = {2017},
      abstract     = {In pediatric patients with brain tumors, both the
                      monitoring of brain tumor therapy and evaluation of
                      treatment response is of paramount importance (1). In
                      particular, the early identification of non-response allows
                      the termination of an ineffective therapy to avoid possible
                      side effects (e.g., bone marrow depression, nausea, fatigue,
                      allergies, and polyneuropathy) and therefore to maintain or
                      even improve life-quality. Furthermore, the early
                      identification of non-response allows an earlier treatment
                      change. For example, in the event of chemotherapy failure,
                      negative side effects can be avoided and an earlier switch
                      to another chemotherapeutic agent is possible before bone
                      marrow reserves are exhausted. Moreover, identification of
                      treatment failure may help reduce costs. To date, this is
                      highly relevant because the expense of newer systemic
                      treatment options (e.g., immunotherapy and targeted therapy
                      options such as tyrosine kinase inhibitors, BRAF inhibitors,
                      and MEK inhibitors) is considerably higher than conventional
                      alkylating chemotherapy.},
      cin          = {INM-3 / INM-4},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406},
      pnm          = {573 - Neuroimaging (POF3-573)},
      pid          = {G:(DE-HGF)POF3-573},
      typ          = {PUB:(DE-HGF)16},
      UT           = {WOS:000408650700015},
      doi          = {10.21037/atm.2017.05.02},
      url          = {https://juser.fz-juelich.de/record/837425},
}